Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI:10.1159/000486812 Fig. 1. Flowchart of included and excluded patients treated with direct-acting antivirals (DAAs) and numbers of patients with hepatocellular carcinoma (HCC). SVR, sustained virologic response. © 2018 S. Karger AG, Basel

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI:10.1159/000486812 Fig. 2. a Cumulative incidence of hepatocellular carcinoma stratified according to response to treatment in the whole direct-acting antiviral (DAA) cohort (p &#3c; 0.001, by log-rank test). b Cumulative incidence of hepatocellular carcinoma stratified according to cirrhosis in the whole DAA cohort (p &#3c; 0.001, by log-rank test). c Cumulative incidence of hepatocellular carcinoma stratified according to response to treatment in the whole interferon (IFN) cohort (p = 0.008, by log-rank test). d Cumulative incidence of hepatocellular carcinoma stratified according to cirrhosis in the whole IFN cohort (p = 0.001, by log-rank test). SVR, sustained virologic response. © 2018 S. Karger AG, Basel

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI:10.1159/000486812 Fig. 3. Flowchart of included and excluded patients treated with interferon-based therapies and numbers of patients with hepatocellular carcinoma (HCC). SVR24, sustained virologic response, undetectable HCV RNA 24 weeks after the end of therapy. © 2018 S. Karger AG, Basel